Common Stock Purchase Agreement, dated March 24, 2006



 EXHIBIT 10.1 
 COMMON STOCK PURCHASE AGREEMENT 
 This COMMON STOCK PURCHASE AGREEMENT (this
“Agreement”) is made as of March 24, 2006 by and between EP MedSystems, Inc., a New Jersey corporation with its principal office at 575 Route 73 North, Building D, West Berlin, New Jersey 08091-9293 (the
“Company”), and each of the several purchasers named in Exhibit A attached hereto (each, a “Purchaser” and collectively, the “Purchasers”). 
 WHEREAS, the Company desires to issue and sell to the Purchasers an aggregate of (i) up to 4,444,500 shares (the “Shares”)
of the authorized but unissued shares of the Company’s common stock, no par value, stated value $0.001 per share (the “Common Stock”); and 
 WHEREAS, each Purchaser, severally, wishes to purchase the number of Shares shown next to its name on Exhibit A hereto, all upon the terms and subject to the conditions set forth in this Agreement. 

NOW THEREFORE, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the parties hereto agree as
follows: 
 1. Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 “Affiliate” of a party means any other Person controlling, controlled by or under common control with the specified Person. For
the purposes of this definition, “control” means the power to direct the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and all of the rules and regulations
promulgated thereunder. 
 “GAAP” means United States generally accepted accounting principles.

 “Majority Purchasers” shall mean Purchasers which, at any given time, hold greater than fifty
percent (50%) of the outstanding Shares. 
 “Material Adverse Effect” shall mean a material
adverse effect on the prospects, condition (financial or other), business, operations, assets, liabilities, or results of operations of the Company and its subsidiaries, taken as a whole. 
 “NASD” means the National Association of Securities Dealers, Inc. 
 “Person” shall mean an individual, corporation, company, partnership, firm, association, joint venture, trust,
unincorporated organization, government, governmental body, agency, political subdivision or other entity. 







 “Registration Rights Agreement” shall mean that certain
Registration Rights Agreement, dated as of the Closing Date, among the Company and the Purchasers. 
 “SEC”
shall mean the Securities and Exchange Commission. 
 “Securities Act” shall mean the Securities
Act of 1933, as amended, and all of the rules and regulations promulgated thereunder. 
 2. Purchase and Sale of Shares. 
 2.1 Purchase and Sale. Subject to and upon the terms and conditions set forth in this Agreement, the Company agrees to issue, sell and
deliver to each Purchaser, and each Purchaser, severally, hereby agrees to purchase from the Company, at the Closing, (i) the number of shares of Common Stock set forth opposite the name of such Purchaser under the heading “Number of
Shares to be Purchased” on Exhibit A hereto, at a purchase price of $2.25 per share. The total purchase price payable by each Purchaser for the number of shares of Common Stock that such Purchaser is hereby agreeing to purchase is
set forth opposite the name of such Purchaser under the heading “Purchase Price” on Exhibit A hereto. The Company shall be obligated to register the Shares pursuant to the terms and conditions set forth in the Registration
Rights Agreement. 
 2.2 Closing. The closing of the transactions contemplated under this Agreement (the
“Closing”) shall take place at 10:00 a.m. at the offices of Mayer, Brown, Rowe & Maw LLP in New York, New York on March 27, 2006, or at such other location, date and time as may be agreed upon between the
Majority Purchasers and the Company (the “Closing Date”). At the Closing, the Company shall authorize its transfer agent to issue to each Purchaser, against delivery of payment for the Shares by wire transfer of immediate
available funds in accordance with the Company’s instructions, one or more stock certificates registered in the name of each Purchaser, representing the number of shares set forth opposite the appropriate Purchaser’s name on
Exhibit A hereto, and bearing the legend set forth in Section 6.2 hereof. Closing documents may be delivered by facsimile with original signature pages sent by overnight courier. 
 2.3 Independent Purchasers. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an
arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby and that each Purchaser has separately negotiated the terms of this Agreement. Nothing contained herein or in any agreement or document relating to
this transaction, and no action taken by any Purchaser, shall be deemed to constitute the Purchasers as, or to create any presumption that the Purchasers are in any way acting in concert or as, a group with respect to the obligations or transaction
hereunder. No Purchaser has relied upon any other Purchaser for advice in entering into the transactions contemplated hereby. 
 3.
Representations and Warranties of the Company. The Company hereby represents and warrants to each of the Purchasers as follows: 
 3.1 Organization and Good Standing. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of New Jersey and has all requisite power and authority, and all necessary
licenses and permits, to own and lease its properties and assets and to conduct its business as now conducted. Each subsidiary as referred 

  

 2 








 
to in the SEC Documents (as hereinafter defined) or the Draft 10-KSB (as hereinafter defined) is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation and has all requisite power and authority, and all necessary licenses and permits, to own and lease its properties and assets and to conduct its business as now conducted. The Company
and its subsidiaries are each qualified to do business as a foreign corporation and are in good standing in all states where the conduct of their respective businesses or their ownership or leasing of property requires such qualification, except
where the failure to so qualify would not have a Material Adverse Effect. The Company does not own or control, directly or indirectly, any interest in any other corporation, partnership, limited liability company, unincorporated business
organization, association, trust or other business entity. 
 3.2 Capitalization. 
 (a) The authorized capital stock of the Company consists of: (i) 5,000,000 shares of preferred stock of the Company, no par value per
share, of which no shares are issued and outstanding; and (ii) 40,000,000 shares of Common Stock, no par value, $.001 stated value per share, of which, immediately prior to the consummation of the transactions contemplated hereby,
(A) 25,970,176 shares are issued and outstanding and all such outstanding shares are validly issued, fully paid and nonassessable; (B) 50,000 shares of Common Stock are held in treasury; (C) 801,708 shares of Common Stock reserved for
issuance pursuant to the Company’s 1995 Long Term Incentive Plan; (D) 180,000 shares of Common Stock reserved for issuance pursuant to the Company’s 1995 Director Option Plan; (E) 990,000 shares of Common Stock reserved for
issuance pursuant to the Company’s 2002 Stock Option Plan; (F) 1,000,000 shares of Common Stock reserved for issuance under the Company’s 2006 Stock Option Plan; (G) 1,000,0000 shares of Common Stock reserved for issuance under
the Company’s 2006 Director Plan; (H) 477,327 shares of Common Stock reserved for issuance upon conversion of the Company’s outstanding Secured Convertible Note issued to Laurus Master Fund, Ltd.; (I) 1,250,050 shares of Common
Stock reserved for issuance upon exercise of outstanding warrants; and (J) 255,000 shares of Common Stock reserved for issuance upon the exercise of outstanding non-plan options. With respect to the 1995 Long Term Incentive Plan, the 1995
Director Option Plan, the 2002 Stock Option Plan, the 2006 Stock Option Plan, the 2006 Director Plan and other non-plan stock options and warrants, an aggregate of 4,016,585 options and warrants have been granted or issued and are outstanding as of
the Closing Date. 
 (b) There are no preemptive or similar rights to purchase or otherwise acquire shares of capital stock of
the Company pursuant to any provision of law or the Amended and Restated Certificate of Incorporation or By-Laws of the Company or by agreement or otherwise. Except as set forth in this Section 3.2 and except as set forth in the SEC
Documents or the Draft 10-KSB, there are no outstanding subscriptions, warrants, options or other rights or commitments of any character to subscribe for or purchase from the Company, or obligating the Company to issue, any shares of capital stock
of the Company or any securities convertible into or exchangeable for such shares. 
 (c) There are no stockholder agreements,
voting agreements, or similar agreements with respect to the Common Stock to which the Company is a party, or to the knowledge of the Company, by or between any stockholders of the Company or any of its Affiliates. 
  

 3 








 3.3 Authorization. The Company has all requisite corporate power to enter into this
Agreement and the Registration Rights Agreement, to issue the Shares and to carry out and perform its obligations under the terms of this Agreement and the Registration Rights Agreement (including, without limitation, the issuance of the Shares).
All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution, delivery and performance of this Agreement and the Registration Rights Agreement and the consummation of the
transactions contemplated herein and therein has been taken or will be taken prior to the Closing Date. When executed and delivered by the Company, each of this Agreement and the Registration Rights Agreement shall constitute the legal, valid and
binding obligation of the Company, enforceable against the Company in accordance with their respective terms, except as such may be limited by bankruptcy, insolvency, reorganization or other laws affecting creditors’ rights generally and by
general equitable principles. 
 3.4 Valid Issuance of the Shares. The Shares being purchased by the Purchasers hereunder will,
upon issuance pursuant to the terms hereof, be validly issued, fully paid and nonassessable, free from all liens, claims, encumbrances with respect to the issuance of such Shares and will not be subject to any preemptive or similar rights. Except
for blue sky filing fees, if any, there are no state or city taxes, fees or other charges payable in connection with the execution or delivery of this Agreement, the Registration Rights Agreement and the Shares. 
 3.5 Financial Statements. The Company has furnished to each Purchaser its audited Statements of Income, Stockholders’ Equity and Cash
Flows for the fiscal year ended December 31, 2004, its audited Balance Sheet as of December 31, 2004, its unaudited Statements of Income, Stockholders’ Equity and Cash Flows for the period from December 31, 2004 through
September 30, 2005 and its unaudited Balance Sheet as of September 30, 2005. All such financial statements are hereinafter referred to collectively as the “Financial Statements.” The Financial Statements have
been prepared in accordance with U.S. generally accepted accounting principles applied on a consistent basis during the periods involved, and fairly present, in all material respects, the financial position of the Company and the results of its
operations as of the date and for the periods indicated thereon, except that the unaudited financial statements may not be in accordance with U.S. generally accepted accounting principles because of the absence of footnotes and are subject to normal
year-end audit adjustments which, individually, and in the aggregate, will not be have a Material Adverse Effect. Since September 30, 2005, to the Company’s knowledge, (i) there has been no development or change (actual or
threatened), individually or in the aggregate, having a Material Adverse Effect, (ii) except as set forth in an SEC Document (as defined below) or the Draft 10-KSB (as defined below), there does not exist any condition reasonably likely to
result in a Material Adverse Effect and (iii) the Company has conducted its business only in the ordinary course consistent with past practice. The Company has no indebtedness, obligations or liabilities of any kind (whether accrued, absolute,
contingent or otherwise, and whether due or to become due) which were not fully reflected in, reserved against or otherwise described in the Financial Statements or the notes thereto, or incurred in the ordinary course of business consistent with
the Company’s past practices, all of which individually and in the aggregate do not or would not have a Material Adverse Effect. 
 3.6
SEC Documents. The Company has made available to each Purchaser, a true and complete copy of the Company’s Annual Report on Form 10-KSB for the year ended December 31, 2004, the Company’s Quarterly Reports on Form 10-QSB
for the three months 

  

 4 








 
ended March 31, 2005, June 30, 2005 and September 30, 2005 and any other statement, report, registration statement (other than
registration statements on Form S-8) or definitive proxy statement filed by the Company with the SEC during the period commencing on December 31, 2004 and ending on the date hereof. The Company will, promptly upon the filing thereof, also make
available to each Purchaser all statements, reports (including, without limitation, Quarterly Reports on Form 10-QSB and Current Reports on Form 8-K), registration statements and definitive proxy statements filed by the Company with the SEC during
the period commencing on the date hereof and ending on the Closing Date (all such materials required to be furnished to each Purchaser pursuant to this sentence or pursuant to the next preceding sentence of this Section 3.6 being called,
collectively, including any amendments thereto, the “SEC Documents”). The Company has made available to each Purchaser a draft (dated March 23, 2006) of the Company’s Annual Report on Form 10-KSB for
the year ended December 31, 2005 (the “Draft 10-KSB”). Since January 1, 2005, the Company has timely made all filings required to be made by it under the Exchange Act and the securities laws of any state, and any
rules and regulations promulgated thereunder. The SEC Documents comply in all material respects with the requirements of the Exchange Act or the Securities Act, as applicable, and none of the SEC Documents contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading, as of their respective filing dates,
except to the extent corrected by a subsequently filed SEC Document filed prior to the date hereof; provided, that, it is hereby acknowledged and agreed that the Company is not making any representation or warranty pursuant to this sentence in
respect of the Draft 10-KSB. The Company is eligible to use a registration statement on Form S-3 with respect to the registration of Registrable Securities (as such term is defined in the Registration Rights Agreement) pursuant to the Registration
Rights Agreement. 
 3.7 Consents. Except for filings under federal and applicable state securities laws and except for Permits
(as defined below), the absence of which either individually or in the aggregate would not have a Material Adverse Effect, all permits, consents, approvals, orders, authorizations of, or declarations to (collectively,
“Permits”) or filings with any federal, state, local or foreign court, governmental or regulatory authority, or other person (including third party consents) required on the part of the Company in connection with the
execution, delivery or performance of this Agreement and the Registration Rights Agreement and the consummation of the transactions contemplated herein and therein have been obtained or will be obtained prior to the Closing Date, and will be
effective as of the Closing Date. 
 3.8 No Conflict. The execution and delivery of this Agreement and the Registration Rights
Agreement by the Company and the consummation of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares) will not (x) conflict with or result in any violation of or default (with or without
notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or to a loss of a material benefit under (i) any provision of the Amended and Restated Certificate of Incorporation
or bylaws of the Company or (ii) any agreement or instrument, Permit, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to the Company, any of its subsidiaries or their respective properties or assets
or (y) result in the creation of any lien, security interest, charge or encumbrance upon the Company’s or any of its subsidiaries’ assets, properties or outstanding capital stock. 
  

 5 








 3.9 Brokers or Finders. Except for C.E. Unterberg, Towbin LLC, a Delaware limited liability
company (the “Placement Agent”), the Company has not dealt with any broker or finder in connection with the transactions contemplated by this Agreement, and, except for certain fees and expenses payable by the Company to the
Placement Agent, the Company has not incurred, and shall not incur, directly or indirectly, any liability for any brokerage or finders’ fees or agents commissions or any similar charges in connection with this Agreement or any transaction
contemplated hereby. 
 3.10 Nasdaq Capital Market. The Common Stock is listed on The Nasdaq Capital Market, and there are no
proceedings to revoke or suspend such listing. The issuance of the Shares will not contravene any NASDAQ Marketplace Rule. The Common Stock is registered pursuant to Section 12(g) of the Exchange Act. The Company has taken no action
designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act, delisting the Common Stock from The Nasdaq Capital Market. The Company has not received any notification
that, and has no knowledge that, the SEC or the NASD is contemplating terminating such listing or registration. The issuance of the Shares does not require stockholder approval, including, without limitation, as may be required pursuant to the
Nasdaq Marketplace Rules. 
 3.11 Absence of Litigation. Except as set forth in the SEC Documents or the Draft 10-KSB, there is
no action, suit or proceeding or, to the Company’s knowledge, any investigation, pending, or to the Company’s knowledge, threatened by or before any governmental body against the Company, its subsidiaries, its activities, properties or
assets or any officer, director, or employee of the Company in connection with such officer’s, director’s or employee’s relationship with, or actions taken on behalf of the Company and in which an unfavorable outcome, ruling or
finding in any said matter, or for all matters taken as a whole, might have a Material Adverse Effect. The foregoing includes, without limitation, any such action, suit, proceeding or investigation that questions this Agreement or the Registration
Rights Agreement or the right of the Company to execute, deliver and perform under same. The Company is not a party to, or subject to the provisions of any order, writ or injunction, judgment or decree of any court or government agency or
instrumentality. 
 3.12 Fiduciary Duties. The Company represents and warrants that, to the best of its knowledge, none of its
directors or officers is or has been the subject of, or a defendant in: (i) an enforcement action or prosecution (or settlement in lieu thereof) brought by a governmental authority relating to a violation of securities, fiduciary or criminal
laws, or (ii) a civil action (or settlement in lieu thereof) brought by stockholders or investors for violation of duties owed to the stockholders or investors. 
 3.13 Title to Property and Assets. Except as disclosed in the SEC Documents or the Draft 10-KSB, each of the Company and its subsidiaries owns its property and assets free and clear of all mortgages,
liens, loans, claims, charges and encumbrances, and except such encumbrances and liens that arise in the ordinary course of business and do not materially impair their respective ownership or use of such property or assets. With respect to property
and assets it leases, the Company is in material compliance with such leases and, to the best of its knowledge, holds a valid leasehold interest free of any liens, charges, claims or encumbrances, 

  

 6 








 
except to the extent any such lien, charge, claim or encumbrance would not have a Material Adverse Effect. 
 3.14 Patents. Trademarks. Proprietary Rights. 
 (a) To the Company’s knowledge, each of the Company and its subsidiaries owns or has the right to use all of the Intellectual Property Rights (as defined below), except where such failure would not have a
Material Adverse Effect on the business, properties or assets of the Company and its subsidiaries, taken as a whole. For purposes of this Agreement, “Intellectual Property Rights” means all patents, copyrights, trademarks,
service marks, trade names, permits, trade secrets, computer programs, software designs and related materials and other intellectual property that are used by the Company or a subsidiary and are material to the conduct of the Company’s or a
subsidiary’s business. 
 (b) To the Company’s knowledge, the Company’s and each subsidiary’s use and
enjoyment of the Intellectual Property Rights do not violate any license or conflict with or infringe the intellectual property rights of others in a manner which would materially and adversely affect the business, assets, properties, operations or
condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole. 
 3.15 Environmental Matters. Except
as set forth in the SEC Documents or the Draft 10-KSB, to the Company’s knowledge, neither the Company nor any of its subsidiaries is in violation of any applicable statute, law or regulation relating to the environment or occupational health
and safety, which violation could reasonably be expected to result in a Material Adverse Effect, and to the best of its knowledge, no expenditures are required in order to comply with any such existing statute, law or regulation, which expenditures
could reasonably be expected to result in a Material Adverse Effect. 
 3.16 Permits. Each of the Company and its subsidiaries
possesses all Permits or similar authority necessary to conduct its business as described in the SEC Documents and the Draft 10-KSB, except where the failure to possess such Permits would not, individually or in the aggregate, have a Material
Adverse Effect on the Company or its subsidiaries (“Material Permits”), and neither the Company nor any such subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.

 3.17 Employees. To the Company’s knowledge, no strike, labor dispute or union organizing activities are pending or
threatened against the Company or any of its subsidiaries by its employees. No employees belong to a union or collective bargaining unit. To the Company’s knowledge, neither the Company nor any of its subsidiaries has any workers’
compensation liabilities. 
 3.18 Tax Matters. The Company has filed all tax returns and reports as required by federal, state,
local, and foreign law and has paid all taxes shown thereon that have become due and payable. Such returns and reports were materially accurate and complete when filed and reflect all taxes and other assessments due thereunder to be paid by the
Company, except those contested by it in good faith. The provision for taxes of the Company included in the provision for accrued liabilities in the Company’s Financial Statements is adequate for taxes due or 

  

 7 








 
accrued as of the dates thereof. The Company has never had any material tax deficiency proposed or assessed against it. 
 3.19 Compliance with Certificate of Incorporation and By-laws; Compliance with Laws. The Company is not in violation or default of any
provisions of its Amended and Restated Certificate of Incorporation or Bylaws. The business and operations of the Company and each of its subsidiaries have been conducted in accordance with all applicable laws, rules and regulations of all
governmental agencies, authorities and instrumentalities (including, without limitation, under the Employee Retirement Income Security Act of 1974, as amended, laws and regulations administered by the Food and Drug Administration, and all laws
relating to the employment of labor), except for such violations which would not, individually or in the aggregate, have a Material Adverse Effect. 
 3.20 Insurance. The Company and each of its subsidiaries maintains insurance of the type and in the amount reasonably adequate for its business, including, but not limited to, insurance covering all real and personal property
owned or leased by the Company against theft, damage, destruction, acts of vandalism, and all other risks customarily insured against by similarly situated companies, all of which insurance is in full force and effect. 
 3.21 Investment Company Act. The Company is not an “investment company” within the meaning of the Investment Company Act
of 1940, as amended (the “Investment Company Act”), and the Company is not directly or indirectly controlled by or acting on behalf of any person that is an “investment company” within the meaning of the
Investment Company Act. 
 3.22 Compliance With Securities Laws. Assuming the accuracy of the representations and warranties of
the Purchasers set forth in Section 4 hereof, the offer and sale by the Company of the Shares are exempt from the registration and prospectus delivery requirements of the Securities Act. Other than pursuant to an effective registration
statement under the Securities Act, the Company has not issued, offered or sold any shares of Common Stock (including for this purpose any securities of the same or a similar class as the Common Stock) within the six (6) month period preceding
the date hereof or taken any other action, or failed to take any action, that, in any such case, would (i) eliminate the availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer
and sale of the Shares as contemplated hereby or (ii) cause the offering of the Shares pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable stockholder approval
provisions, including, without limitation, under the rules and regulations of the NASD, as applicable. The Company shall not directly or indirectly take, and shall not permit any of its directors, officers or Affiliates directly or indirectly to
take, any action (including, without limitation, any offering or sale to any Person of the Shares or any Common Stock) that will make unavailable the exemption from registration under the Securities Act being relied upon by the Company for the offer
and sale to the Purchasers of the Shares as contemplated by this Agreement, including, without limitation, the filing of a registration statement under the Securities Act. No form of general solicitation or advertising within the meaning of Rule
502(c) under the Securities Act has been used or authorized by the Company or any of its officers, directors or Affiliates in connection with the 

  

 8 








 
offer or sale of the Shares as contemplated by this Agreement or any other agreement to which the Company is a party. 
 3.23 Registration Rights. Except as set forth in the SEC Documents or the Draft 10-KSB, there are no Persons (except the Purchasers and
their permitted transferors hereunder) with registration or other similar rights to have any securities registered pursuant to the Registration Statement or otherwise registered by the Company under the Securities Act which have not been satisfied.

 3.24 Related Party Transactions. Except as set forth in the SEC Documents or the Draft 10-KSB, neither the Company nor any
of its officers, directors or Affiliates nor any family member of any officer, director or Affiliate of the Company has borrowed any moneys from or has outstanding any indebtedness or other similar obligations to the Company. Except as set forth in
the SEC Documents or the Draft 10-KSB, no director or Affiliate nor any family member of any officer, director or Affiliate of the Company (i) owns any direct or indirect interest constituting more than a 1% equity (or similar profit
participation) interest in, or controls or is a director, officer, partner, member or employee of, or consultant or lender to or borrower from, or has the right to participate in the profits of, any person or entity which is a participant in any
transaction to which the Company or any subsidiary is a party or (ii) is a party to any contract, agreement, commitment or other arrangement with the Company or any subsidiary or (iii) has entered into any transaction with the Company or
any subsidiary that would be required to be disclosed under Item 404 of Regulation S-K. 
 3.25 Contracts. All contracts
and agreements filed or required to be filed as exhibits to the SEC Documents filed prior to the date hereof, except such contracts and agreements that have expired by their own terms (collectively, “Contracts”) are in full
force and effect and constitute legal, valid and binding obligations of the Company and, to the best knowledge of the Company, the other parties thereto; the Company and, to the best knowledge of the Company, each other party thereto, have performed
in all material respects all obligations required to be performed by them under the Contracts, and no material violation or default exists in respect thereof, nor any event that with notice or lapse of time, or both, would constitute a default
thereof, on the part of the Company or, to the best knowledge of the Company, any other party thereto; none of the Contracts is currently being renegotiated; and the validity, effectiveness and continuation of all Contracts will not be materially
adversely affected by the transactions contemplated by this Agreement. 
 3.26 Disclosure. Neither this Agreement nor the SEC
Documents nor the Draft 10-KSB taken together contain any untrue statement of a material fact nor omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the circumstances under which they
were made, not misleading. To the Company’s knowledge, neither it nor, any Person on its behalf, has provided any of the Purchasers or their agents or counsel with any information that constitutes, or might reasonably be expected to constitute,
material, non-public information except for (x) the existence of this transaction and the terms and conditions hereof, and (y) such material non-public information as is contained in the Draft 10-KSB. The Company intends to file the
Company’s Annual Report on Form 10-KSB for the year ended December 31, 2005 with the SEC on or prior to March 31, 2006, which Annual Report on Form 10-KSB shall be in a form substantially similar to the Draft 10-KSB. The Company


  

 9 








 
understands and confirms that each of such Purchasers will rely on the foregoing representations in effecting transactions in securities of the Company.

 3.27 Sarbanes-Oxley. The Chief Executive Officer and the Chief Financial Officer of the Company have signed, and the Company
has furnished to the SEC, all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Such certifications contain no qualifications or exceptions to the matters certified therein and have not been modified or withdrawn;
and neither the Company nor any of its officers has received notice from any governmental entity questioning or challenging the accuracy, completeness, form or manner of filing or submission of such certifications. 
 3.28 Disclosure Controls and Procedures. The Company and its subsidiaries maintain a system of disclosure controls and procedures (as
defined in Rules 13a-15 and 15d-15 of the Exchange Act). To the Company’s knowledge, the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files
or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. 
 4.
Representations, Warranties and Agreements of the Purchasers. Each Purchaser severally for itself, and not jointly with the other Purchasers, represents and warrants to, and agrees with, the Company as follows: 
 4.1 Authorization. Such Purchaser has all requisite power under its constituent documents to enter into each of this Agreement and the
Registration Rights Agreement and to carry out and perform its obligations under the terms of this Agreement and the Registration Rights Agreement. All action on the part of such Purchaser and, if applicable, its officers, directors, stockholders,
managers, members and equityholders necessary for the authorization, execution, delivery and performance of this Agreement and the Registration Rights Agreement and the consummation of the transactions contemplated herein and therein has been taken.
When executed and delivered, each of this Agreement and the Registration Rights Agreement will constitute the legal, valid and binding obligation of such Purchaser, enforceable against such Purchaser in accordance with its terms, except as such may
be limited by bankruptcy, insolvency, reorganization or other laws affecting creditors’ rights generally and by general equitable principles. 
 4.2 Purchase Entirely for Own Account. Such Purchaser is acquiring the Shares being purchased by it hereunder for investment, for its own account, and not for resale or with a view to distribution thereof in violation of the
Securities Act. 
 4.3 Investor Status; Etc. Such Purchaser certifies and represents to the Company that at the time such
Purchaser acquires any of the Shares, such Purchaser will be an “Accredited Investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act and was not organized for the purpose of
acquiring the Shares. Such Purchaser’s financial condition is such that it is able to bear the risk of holding the Shares for an indefinite period of time and the risk of loss of its entire investment. Such Purchaser has sufficient knowledge
and experience in investing in companies similar to the Company in terms of the Company’s stage of development so as to be able to evaluate the risks and merits of its investment in the Company. Such 

  

 10 








 
Purchaser has received and carefully reviewed descriptive materials relating to the Company and any other materials relating thereto that such Purchaser has
requested. Such Purchaser has had an opportunity to ask questions of and receive answers from the authorized representatives of the Company, and to review any relevant documents and records concerning the business of the Company and the terms and
conditions of this investment, and that any such questions have been answered to such Purchaser’s full satisfaction. No Person other than the Company or its authorized representatives, has offered the securities to the Purchaser. Such Purchaser
is acquiring the Shares in the ordinary course of business for such Purchaser’s own account as principal (and not as a nominee or agent), for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization
thereof, in whole or in part, in any manner in violation of applicable United States federal or state securities laws or the rules or regulations promulgated thereunder. Such Purchaser has made no agreement, direct or indirect, with any other Person
regarding any sale, transfer, assignment or other disposition of any interest in the Shares. Such Purchaser is aware that, in the view of the SEC and certain state securities commissions, a purchase of the Shares now with an intent to resell by
reason of any foreseeable specific contingency or anticipated change in market values or any change in the condition of the Company, or in connection with a contemplated liquidation or settlement of any loan obtained for the acquisition of the
Shares and for which the Shares were pledged as security, would represent an intent inconsistent with this representation. Such Purchaser further represents and agrees that if, contrary to the foregoing intentions, such Purchaser should later desire
to dispose of or transfer any of the Shares in any manner, such Purchaser shall not do so without first complying with the provisions of Section 6.1. Such Purchaser understands that no federal or state agency has passed upon or made any
recommendation or endorsement of an investment in the Shares. The foregoing shall in no way limit or modify the representations of the Company set forth in Section 3 hereof. 
 4.4 Shares Not Registered. Such Purchaser understands that the Shares have not been registered under the Securities Act, by reason of their
issuance by the Company in a transaction exempt from the registration requirements of the Securities Act, and that the Shares must continue to be held by such Purchaser unless a subsequent disposition thereof is registered under the Securities Act
or is exempt from such registration. The Purchaser understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various
conditions, and that, if applicable, Rule 144 may afford the basis for sales only in limited amounts. 
 4.5 No Conflict. The
execution and delivery of this Agreement and the Registration Rights Agreement by such Purchaser and the consummation by it of the transactions contemplated hereby and thereby will not conflict with or result in any violation of or default by such
Purchaser (with or without notice or lapse of time, or both) under (i) any provision of the organizational documents of such Purchaser or (ii) any judgment, Order, statute, law, ordinance, rule or regulations, applicable to such Purchaser
or its respective properties or assets. 
 4.6 Brokers. Such Purchaser has not retained, utilized or been represented by any
broker or finder in connection with the transactions contemplated by this Agreement. 
 4.7 Consents. All consents, approvals,
orders and authorizations required on the part of such Purchaser in connection with the execution, delivery or performance of this Agreement 

  

 11 








 
and the Registration Rights Agreement and the consummation of the transactions contemplated herein have been obtained and are effective as of the Closing
Date. 
 4.8 Agreement with Respect to Short Sales. Neither the Purchasers nor any of their respective Affiliates nor any
person acting on their behalf has engaged in, or its otherwise subject to, any “short sale” (as such term is defined in Rule 3b-3 under the Securities Exchange Act of 1934, as amended) or any other hedging transaction in respect of the
Common Stock that has established, as of the date hereof, a net short position with respect to the Common Stock. Since the time that the Purchaser was first contacted by the Company or any other person or entity regarding the investment in the
Company contemplated by this Agreement, neither such Purchaser nor any of its Affiliates nor any person acting on their behalf has entered into any “short sale” (as such term is defined in Rule 3b-3 under the Securities Exchange Act of
1934, as amended) in respect of the Company’s Common Stock and none of the Purchaser nor any of its Affiliates nor any person acting on their behalf will enter into any such “short sale” at any time prior to the Closing Date.

 4.9 Material Non-Public Information. Such Purchaser acknowledges that the United States securities laws prohibit any person
who has received any material non-public information from an issuer or any affiliate thereof from purchasing or selling securities of such issuer or from communicating such information to any other person under circumstances in which it is
reasonably foreseeable that such person is likely to purchase or sell such securities. Such Purchaser shall abide by such prohibitions, and will comply in all respects with all other laws and regulations implicated by the receipt, production or use
of any material non-public information regarding the Company. 
 5. Conditions Precedent. 
 5.1 Conditions to the Obligation of the Purchasers to Consummate the Closing. The obligation of each Purchaser to consummate the Closing
and to purchase and pay for the Shares being purchased by it pursuant to this Agreement is subject to the satisfaction of the following conditions precedent (or waiver by such Purchaser): 
 (a) The representations and warranties contained herein of the Company that are qualified as to “materiality” shall be true and
correct, and the representations and warranties contained herein of the Company that are not so qualified shall be true and correct in all material respects, in each case, as of the date of this Agreement and as of the Closing Date (except for such
representations and warranties which are made expressly as of a specified date or period, which shall be true and correct or true and correct in all material respects, as herein above required, as of such specified date or period). 
 (b) The Company shall have performed all covenants, agreements, obligations and conditions herein required to be performed or observed by
the Company on or prior to the Closing Date. 
 (c) Prior to the Closing Date, no event shall have occurred which has had a
Material Adverse Effect shall have occurred. 
  

 12 








 (d) No suit, action, or other proceeding challenging this Agreement or the transactions
contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, shall have been instituted before any court, arbitrator or governmental body, agency or official and shall be pending. 
 (e) The purchase of and payment for the Shares by such Purchasers shall not be prohibited by any law or governmental order or regulation.
All necessary consents, approvals, licenses, Permits, orders and authorizations of, or registrations, declarations and filings with, any governmental or administrative agency or of any other person with respect to any of the transactions
contemplated hereby (including, without limitation, the issuance of the Shares) shall have been duly obtained or made and shall be in full force and effect. 
 (f) The Company shall have complied with all applicable requirements of federal and state securities or “blue sky” laws
with respect to the issuance of the Shares, and each Purchaser, at such Purchaser’s request, shall have been provided reasonable evidence thereof. 
 (g) The Common Stock of the Company (i) shall be designated for quotation or listed on The Nasdaq Capital Market and (ii) shall not have been suspended from trading on The Nasdaq Capital Market. 

(h) The Registration Rights Agreement shall have been executed and delivered by the Company. 
 (i) A certificate shall have been delivered by the Company, signed by its President, Chief Executive Officer or Chief Financial Officer,
dated as of the Closing Date, certifying as to the fulfillment of the conditions specified in Sections 5.1(a), (b), (c), (d), (e), (f), (g) and (m). 
 (j) The Company shall have delivered to each Purchaser an opinion of counsel for the Company, dated the Closing Date, in substantially the
form of Exhibit B attached hereto. 
 (k) A stock certificate shall have been delivered by the Company, registered in
the name of such Purchaser or nominee as designated by such Purchaser in writing, representing the number of shares of Common Stock purchased by such Purchaser, free of all restrictive and other legends (except as provided in Section 6.2
hereof), against payment of the purchase price therefor by wire transfer of immediately available funds to such account or accounts as the Company shall designate in writing. 
 (l) All instruments and corporate proceedings in connection with the transactions contemplated by this Agreement to be consummated at the
Closing shall be satisfactory in form and substance to such Purchaser, and such Purchaser shall have received copies (executed or certified, as may be appropriate) of all documents which such Purchaser may have reasonably requested in connection
with such transactions. 
 (m) No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to
prohibit, alter, prevent or materially delay the Closing, shall 

  

 13 








 
have been instituted before any court, arbitrator or governmental body, agency or official and shall be pending. 
 (n) The Company shall have delivered to the Purchasers a certificate of the Company executed by the Company’s Secretary attaching and
certifying to the truth and correctness of (i) the Company’s Amended and Restated Certificate of Incorporation, (ii) the Company’s Bylaws and (iii) the resolutions adopted by the Company’s Board of Directors in
connection with the transactions contemplated by this Agreement. 
 5.2 Conditions to the Obligation of the Company to Consummate the
Closing. The obligation of the Company to consummate the Closing, to issue and sell to each Purchaser the Shares to be purchased by it at the Closing is subject to the satisfaction of the following conditions precedent (or waiver by the
Company): 
 (a) The representations and warranties contained herein of such Purchaser shall be true and correct on and as of
the Closing Date with the same force and effect as though made on and as of the Closing Date (it being understood and agreed by the Company that, in the case of any representation and warranty of each Purchaser contained herein which is not
hereinabove qualified by application thereto of a materiality standard, such representation and warranty need be true and correct only in all material respects in order to satisfy as to such representation or warranty the condition precedent set
forth in the foregoing provisions of this Section 5.2(a)). 
 (b) The Registration Rights Agreement shall have
been executed and delivered by each Purchaser. 
 (c) Such Purchaser shall have performed all obligations and conditions
herein required to be performed or observed by it on or prior to the Closing Date. 
 (d) No proceeding challenging this
Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, shall have been instituted before any court, arbitrator or governmental body, agency or official and shall be pending.

 (e) The sale of the Shares by the Company shall not be prohibited by any law or governmental order or regulation. All
necessary consents, approvals, licenses, Permits, orders and authorizations of, or registrations, declarations and filings with, any governmental or administrative agency or of any other person with respect to any of the transactions contemplated
hereby shall have been duly obtained or made and shall be in full force and effect. 
 (f) Such Purchaser shall have executed
and delivered to the Company an executed Investor Questionnaire, in substantially the form attached hereto as Exhibit C, pursuant to which each such Purchaser shall provide information necessary to confirm each such Purchaser’s status as
an “accredited investor” (as such term is defined in Rule 501 promulgated under the Securities Act). 
 (g)
The Company shall have received executed agreements (which may be a counterpart signature to this Agreement) from each of the Purchasers to purchase, in accordance 

  

 14 








 
with this Agreement, the number of shares of Common Stock set forth on Exhibit A opposite its name under the heading “Number of Shares to
be Purchased.” 
 (h) All instruments and corporate proceedings in connection with the transactions contemplated
by this Agreement to be consummated at the Closing shall be satisfactory in form and substance to the Company, and the Company shall have received counterpart originals, or certified or other copies of all documents, including, without limitation,
records of corporate or other proceedings, which it may have reasonably requested in connection therewith. 
 (i) No Purchaser
nor any of its Affiliates nor any person acting on behalf of such Persons will have entered into for a period of five (5) days prior to the Closing Date, any “short sale” (as such term is defined in Rule 3b-3 under the Securities
Exchange Act of 1934, as amended). 
 (j) Purchasers and other investors shall have committed, pursuant to the terms hereof
and pursuant to any other agreement to purchase Shares in connection with the offering contemplated hereby, to purchase an aggregate of at least 4,000,000 Shares. 
 6. Transfer; Legends. 
 6.1 Securities Law Transfer Restrictions. No Purchaser shall sell,
assign, pledge, transfer or otherwise dispose or encumber any of the Shares being purchased by it hereunder, except: (i) pursuant to an effective registration statement under the Securities Act or (ii) pursuant to an available exemption
from registration under the Securities Act and applicable state securities laws and, if reasonably requested by the Company, upon delivery by such Purchaser of an opinion of counsel reasonably satisfactory to the Company to the effect that the
proposed transfer is exempt from registration under the Securities Act and applicable state securities laws. Any transfer or purported transfer of the Shares in violation of this Section 6.1 shall be voidable by the Company; provided,
however, that no opinion will be required in connection with (1) a public sale or transfer of Shares pursuant to an effective registration statement in connection with which such Purchaser represents in writing to the Company that such
Shares have been or are being sold pursuant to such registration statement; (2) a public sale of Shares pursuant to Rule 144 under the Securities Act if such Purchaser has delivered to the Company a customary and accurate Rule 144 broker’s
and seller’s representation letter; or (3) a sale of shares pursuant to Rule 144(k) under the Securities Act if such Purchaser has delivered to the Company a customary and accurate Rule 144 seller’s representation letter. The Company
shall not register any transfer of the Shares in violation of this Section 6.1. The Company may, and may instruct any transfer agent for the Company, to place such stop transfer orders as may be required on the transfer books of the
Company in order to ensure compliance with the provisions of this Section 6.1. 
  

 15 








 6.2 Legends. Each certificate representing any of the Shares shall be endorsed with a
legend in substantially the form set forth below, and each Purchaser covenants that, except to the extent such restrictions are waived by the Company, it shall not transfer the shares represented by any such certificate without complying with the
restrictions on transfer described in this Agreement and the legends endorsed on such certificate: 
 THE SHARES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY ONLY BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF
PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND SUCH LAWS OR (II) AN EXEMPTION FROM REGISTRATION UNDER SAID ACT, AND TO THE EXTENT PERMITTED BY SECTION 6.1 OF THE COMMON STOCK PURCHASE AGREEMENT PURSUANT TO WHICH
THE SHARES REPRESENTED HEREBY WERE ACQUIRED, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT AND SUCH LAWS. 
 6.3 Removal of Legends. Upon the earlier of (i) the effectiveness of the Registration Statement (as defined in the Registration Rights
Agreement) covering resale of the Shares under the Securities Act or (ii) the Shares becoming eligible for resale under Rule 144(k) promulgated under the Securities Act, the Company shall (A) deliver to the transfer agent for the Common
Stock (the “Transfer Agent”) irrevocable instructions that the Transfer Agent shall reissue a certificate representing the Shares without legends upon receipt by such Transfer Agent of the legended certificates for such
Shares, together with either (1) a customary representation by the applicable Purchaser that Rule 144(k) promulgated under the Securities Act applies to the Shares represented thereby or (2) a statement by the Purchaser that such Purchaser
has sold the Shares represented thereby in accordance with the Plan of Distribution contained in the Registration Statement, and (B) cause its counsel to deliver to the Transfer Agent one or more blanket opinions to the effect that the removal
of such legends in such circumstances may be effected under the Securities Act. From and after the earlier of such dates, upon a Purchaser’s written request, the Company shall promptly cause certificates evidencing the Purchaser’s Shares
to be replaced with certificates which do not bear such restrictive legends. When the Company is required to cause unlegended certificates to replace previously issued legended certificates, if unlegended certificates are not delivered to a
Purchaser within five (5) business days of submission by that Purchaser of legended certificate(s) to the Transfer Agent as provided above, the Company shall be liable to the Purchaser for liquidated damages in an amount equal to 1.0% of the
aggregate purchase price of the Shares evidenced by such certificate(s) for each thirty (30) day period (pro rated for any period of less than 30 days) beyond such five (5) business days that the unlegended certificates have not been so
delivered. 
 7. Termination; Liabilities Consequent Thereon. This Agreement may be terminated and the transactions contemplated
hereunder abandoned at any time prior to the Closing only as follows: 
 (a) with respect to a Purchaser, by such Purchaser,
upon notice to the Company if the conditions set forth in Section 5.1 shall not have been satisfied on or prior to March 27, 2006; or 
  

 16 








 (b) with respect to a Purchaser, by the Company, upon notice to such Purchaser if the
conditions set forth in Section 5.2 to be satisfied by such Purchaser shall not have been satisfied on or prior to March 27, 2006; or 
 (c) at any time by mutual agreement of the Company and Purchasers who represent at least fifty percent (50%) of the Shares being sold hereunder; or 
 (d) with respect to a Purchaser, by such Purchaser, if there has been any breach of any representation or warranty or any material breach
of any covenant of the Company contained herein and the same has not been cured within 15 days after notice thereof (it being understood and agreed by each Purchaser that, in the case of any representation or warranty of the Company contained herein
which is not hereinabove qualified by application thereto of a materiality standard, such representation or warranty will be deemed to have been breached for purposes of this Section 7.1(d) only if such representation or warranty was not
true and correct in all material respects at the time such representation or warranty was made by the Company); or 
 (e) by
the Company with respect to a Purchaser, if there has been any breach of any representation, warranty or any material breach of any covenant of such Purchaser contained herein and the same has not been cured within 15 days after notice thereof (it
being understood and agreed by the Company that, in the case of any representation and warranty of the Purchaser contained herein which is not hereinabove qualified by application thereto of a materiality standard, such representation or warranty
will be deemed to have been breached for purposes of this Section 7.1(e) only if such representation or warranty was not true and correct in all material respects at the time such representation or warranty was made by such Purchaser).

 Any termination pursuant to this Section 7 shall be without liability on the part of any party, unless such termination is the
result of a material breach of this Agreement by a party to this Agreement in which case such breaching party shall remain liable for such breach notwithstanding any termination of this Agreement. 
 8. Miscellaneous Provisions. 
 8.1
Use of Proceeds. The Company shall use the net proceeds from the sale of the Shares for general corporate and working capital purposes and may use a portion of such proceeds to retire certain debt obligations of the Company.

 8.2 Filings. The Company shall make all necessary filings with the SEC and “blue sky” filings required to
be made by the Company in connection with the sale of the Shares to the Purchasers as required by all applicable laws, and shall provide a copy thereof to the Purchasers promptly after such filing. 
 8.3 Public Statements or Releases. Each of the parties to this Agreement agrees that it shall not make, issue, or release any announcement,
whether to the public generally, or to any of its suppliers or customers, with respect to this Agreement or the transactions provided for herein, or make any statement or acknowledgment of the existence of, or reveal the status of, this Agreement or
the transactions provided for herein, without the prior consent of the other parties, which shall not be unreasonably withheld or delayed. Notwithstanding the foregoing, nothing in this Section 8.3 shall prevent any party hereto from
making such public announcements or filings 

  

 17 








 
as it may consider necessary in order to satisfy its legal obligations, or from releasing a public statement acceptable to each of the parties hereto upon
the completion of the offering contemplated hereby. By 8:30 a.m. (New York time) on the first business day following the date hereof, the Company will issue a press release acceptable to each of the parties hereto describing the transactions
contemplated by this Agreement. As soon as possible but not later than the first business day following the Closing Date, the Company will issue a press release acceptable to each of the parties hereto describing the closing of the transactions
contemplated by this Agreement, and promptly thereafter file a Current Report on Form 8-K with the SEC, attaching such press release. 
 8.4
Further Assurances. The parties agree to cooperate fully to execute such further instruments, documents and agreements and to give such further written assurances, as may be reasonably requested by any party to better evidence and
reflect the transactions described herein and contemplated hereby, and to carry into effect the intents and purposes of this Agreement. 
 8.5 Notification of Effectiveness of Registration Statement. The Company covenants that it will provide written notice to each Purchaser (which notice may be in electronic form) that the Company’s registration statement
on Form S-3 registering the Shares sold hereunder to the Purchasers has been declared effective by the SEC, which notice shall be given promptly after the Company has received notice of such effectiveness from the SEC. 
 8.6 Rights Cumulative. Each and all of the various rights, powers and remedies of the parties hereto shall be considered to be cumulative
with and in addition to any other rights, powers and remedies which such parties may have at law or in equity in the event of the breach of any of the terms of this Agreement. The exercise or partial exercise of any right, power or remedy shall
neither constitute the exclusive election thereof nor the waiver of any other right, power or remedy available to such party. 
 8.7
Pronouns. All pronouns or any variation thereof shall be deemed to refer to the masculine, feminine or neuter, singular or plural, as the identity of the person, persons, entity or entities may require. 
 8.8 Notices. 
 (a) Any notices, reports or other correspondence (hereinafter collectively referred to as “correspondence”) required or permitted to be given hereunder shall be sent by postage prepaid first class mail, courier or facsimile
or delivered by hand to the party to whom such correspondence is required 
 or permitted to be given hereunder. The date of giving any notice shall be the
date of its actual receipt. 
 (b) All correspondence to the Company shall be addressed as follows: 
 EP MedSystems, Inc. 
 575 Route 73 North 
 Building D 
 West Berlin, New Jersey 08091-9293 
  

 18 








 Attention: President and Chief Executive Officer 
 Facsimile: (856) 753-8544 
 with a copy to: 
 Mayer, Brown, Rowe & Maw LLP 
 1675 Broadway 
 New York, NY 10019 
 Attention: Thomas M. Vitale, Esq. 
 Facsimile: (212) 262-1910 
 (c) All correspondence to any Purchaser shall be sent to such Purchaser at the address set forth in Exhibit A. 
 (d) Any Person may change the address to which correspondence to it is to be addressed by notification as provided for herein. 
 8.9 Captions. The captions and paragraph headings of this Agreement are solely for the convenience of reference and shall not affect its interpretation. 
 8.10 Severability. Should any part or provision of this Agreement be held unenforceable or in conflict with the applicable laws or
regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable
manner, and the remainder of this Agreement shall remain binding upon the parties hereto. 
 8.11 Governing Law; Injunctive
Relief. 
 (a) This Agreement shall be governed by and construed and enforced in accordance with the internal and
substantive laws of the State of New York and without regard to any conflicts of laws concepts that would apply the substantive law of any other jurisdiction. 
 (b) Each of the parties hereto acknowledges and agrees that damages will not be an adequate remedy for any material breach or violation
of this Agreement if such material breach or violation would cause immediate and irreparable harm (an “Irreparable Breach”). Accordingly, in the event of a threatened or ongoing Irreparable Breach, each party hereto shall be
entitled to seek, in any state or federal court in the State of New York, equitable relief of a kind appropriate in light of the nature of the ongoing or threatened Irreparable Breach, which relief may include, without limitation, specific
performance or injunctive relief; provided, however, that if the party bringing such action is unsuccessful in obtaining the relief sought, the moving party shall pay the non-moving party’s costs, including actual attorney’s fees, incurred
in connection with defending such action. Such remedies shall not be the parties’ exclusive remedies, but shall be in addition to all other remedies provided in this Agreement. 
 8.12 Waiver. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more
instances, shall be deemed to be, or be 

  

 19 








 
construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this
Agreement. 
 8.13 Fees, Costs and Expenses. All fees, costs and expenses (including attorneys’ fees and expenses)
incurred by any party hereto in connection with the preparation, negotiation and execution of this Agreement and the exhibits hereto and the consummation of the transactions contemplated hereby and thereby (including the costs associated with any
filings with, or compliance with any of the requirements of, any governmental authorities), shall be the sole and exclusive responsibility of such party. 
 8.14 Assignment. The rights and obligations of the parties hereto shall inure to the benefit of and shall be binding upon the authorized successors and permitted assigns of each party. The Company shall
not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Majority Purchasers. Any Purchaser may assign its rights under this Agreement to any person to whom the Purchaser assigns or transfers any
Shares, provided that such transferee agrees in writing to be bound by the terms and provisions of this Agreement, and such transfer is in compliance with the terms and provisions of this Agreement and permitted, with the approval of counsel to the
Company, by federal and state securities laws. 
 8.15 Survival. The respective representations and warranties given by the
parties hereto, and the other covenants and agreements contained herein, shall survive the Closing Date and the consummation of the transactions contemplated herein for a period of two years, without regard to any investigation made by any party.

 8.16 Entire Agreement. This Agreement and exhibits attached hereto and incorporated herewith constitute the entire agreement
between the parties hereto respecting the subject matter hereof and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof, whether written or oral. 
 8.17 Amendments. No modification, alteration, waiver or change in any of the terms of this Agreement shall be valid or binding upon the
parties hereto unless made in writing and duly executed by the Company and (a) prior to Closing, Purchasers who represent at least 66  2/3% of the Shares being sold hereunder or (b) following Closing, Purchasers holding at least 66  2/3% of the Shares; provided, however, that, in each case, no such amendment shall increase the obligations of any Purchaser without such Purchaser’s written consent. 

8.18 Confidential Information. Each of the Company and each Purchaser agrees to keep confidential, and not to disclose to or use for the
benefit of any third party, the terms of this Agreement or any other information which at any time is communicated by the other party as being confidential, without the prior written approval of the other party; provided, however, that this
provision shall not apply to information which, at the time of disclosure, is already part of the public domain (except by breach of this Agreement) and information which is required to be disclosed by law (including, without limitation, pursuant to
Item 601(b)(10) of Regulation S-K under the Securities Act and the Exchange Act) and provided further the Company will not furnish confidential information to a Purchaser without (i) informing such Purchaser regarding the nature of such
information and (ii) receiving the prior express written agreement of such 

  

 20 








 
Purchaser. Notwithstanding anything herein to the contrary, any party to this Agreement (and any employee, representative, or other agent of any party to
this Agreement) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that
are provided to it relating to such tax treatment and tax structure. However, any such information relating to the tax treatment or tax structure is required to be kept confidential to the extent necessary to comply with any applicable federal or
state securities laws. 
 8.19 Stock Splits, Dividends and other Similar Events. The provisions of this Agreement shall be
appropriately adjusted to reflect any stock split, stock dividend, reorganization or other similar event that may occur with respect to the Company after the date hereof. 
 8.19 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 
 [The remainder of this page has been intentionally left blank; signature page follows.] 
  

 21 








 IN WITNESS WHEREOF, the parties hereto have executed this Common Stock Purchase Agreement as of the day
and year first above written. 
  

			
	EP MEDSYSTEMS, INC.
		
	By:	 	 /s/ Matthew C. Hill

		 	 Name: Matthew C. Hill

		 	 Title: Chief Financial Officer



 THE PURCHASER’S SIGNATURE TO THE INVESTOR QUESTIONNAIRE DATED EVEN DATE HEREWITH SHALL CONSTITUTE
THE PURCHASER’S SIGNATURE TO THIS COMMON STOCK PURCHASE AGREEMENT. 
  

 22 








 Exhibit A 
  

								
	 PURCHASER
	  	 ADDRESS
	  	 NUMBER
 OF SHARES
TO BE
PURCHASED
	  	AGGREGATE
PURCHASE
PRICE ($)
	SRB Greenway Capital QP, L.P.	  	 300 Crescent Court, Suite 1111
 Dallas, Texas
75201
	  	468,000	  	$	1,053,000.00
	SRB Greenway Offshore Operating Fund, L.P.	  	 300 Crescent Court, Suite 1111
 Dallas, Texas
75201
	  	28,000	  	$	63,000.00
	SRB Greenway Capital, L.P.	  	 300 Crescent Court, Suite 1111
 Dallas, Texas
75201
	  	59,555	  	$	133,998.75
	Walker Smith Capital (Q.P.), L.P.	  	 300 Crescent Court, Suite 1111
 Dallas, Texas
75201
	  	171,200	  	$	385,200.00
	Walker Smith Capital, L.P.	  	 300 Crescent Court, Suite 1111
 Dallas, Texas
75201
	  	20,000	  	$	45,000.00
	Walker Smith International Fund, Ltd.	  	 300 Crescent Court, Suite 1111
 Dallas, Texas
75201
	  	258,055	  	$	580,623.75
	HHMI Investments, L.P.	  	 300 Crescent Court, Suite 1111
 Dallas, Texas
75201
	  	96,300	  	$	216,675.00
	SF Capital Partners Ltd.	  	 3600 South Lake Drive
 St. Francis, WI
53235
	  	1,000,000	  	$	2,250,000.00
	Shea Ventures, LLC	  	 655 Brea Canyon Road
 Walnut, CA 91789
	  	666,667	  	$	1,500,000.75
	Pat L. Gordon	  	 2009 Sharon Lane
 Austin, Texas 78703
	  	466,667	  	$	1,050,000.75
	CE Unterberg Towbin Capital Partners I, L.P.	  	 350 Madison Avenue
 New York, NY 10017
	  	121,112	  	$	272,502.00
	Thomas I. Unterberg Trustee, Ellen U. Celli Family Trust U/A/ 3/25/93	  	 c/o CE Unterberg Towbin
 350 Madison Avenue

New York, NY 10017
	  	22,222	  	$	49,999.50
	Ellen U. Celli	  	 c/o CE Unterberg Towbin
 350 Madison Avenue

New York, NY 10017
	  	22,222	  	$	49,999.50
	Emily U. Satloff	  	 c/o CE Unterberg Towbin
 350 Madison Avenue

New York, NY 10017
	  	22,222	  	$	49,999.50
	NFS/FMTC IRA FBO Thomas I. Unterberg	  	 c/o CE Unterberg Towbin
 350 Madison Avenue

New York, NY 10017
	  	22,222	  	$	49,999.50
	Thomas I. Unterberg	  	 c/o CE Unterberg Towbin
 350 Madison Avenue

New York, NY 10017
	  	66,666	  	$	149,998.50
	Marjorie & Clarence E. Unterberg Foundation Inc.	  	 c/o CE Unterberg Towbin
 350 Madison Avenue

New York, NY 10017
	  	44,444	  	$	99,999.00
	Declaration of Trust by Thomas I. Unterberg U/A 8/7/96	  	 c/o CE Unterberg Towbin
 350 Madison Avenue

New York, NY 10017
	  	22,222	  	$	49,999.50
	2001 Candice N. Pell Trust	  	 40 Ramland Road South, Suite 10
 Orangeburg, NY
10962
	  	100,000	  	$	225,000.00
	2001 Jessica N. Pell Trust	  	 40 Ramland Road South, Suite 10
 Orangeburg, NY
10962
	  	100,000	  	$	225,000.00








 Exhibit B 
 Form of Mayer, Brown, Rowe & Maw LLP Opinion 
 See attached. 







 Exhibit C 
 Form of Investor Questionnaire